Our Services
Medical Information
Helpful Resources
Published on: 9/26/2026
Peptides marketed for weight loss fall into two groups: FDA-approved incretin medications such as semaglutide, liraglutide, and tirzepatide, and unapproved research peptides such as AOD-9604, CJC-1295, ipamorelin, and tesamorelin. Clinical trials show the incretin drugs work, producing average body weight reductions of roughly 10% to 20% over a year when paired with diet and activity changes, while growth hormone releasing peptides have little reliable evidence for fat loss and are frequently sold through unregulated channels. Results, side effects, dosing, cost, and long term safety differ significantly from one peptide to another, and weight regain is common after stopping. There are several important factors to consider, including whether an underlying medical condition is driving weight changes, so review the complete details below before deciding.
If unexplained weight gain, fatigue, appetite changes, or other symptoms are part of your picture, a medication is only useful once you know what is actually going on. Take a free, instant, online symptom check to see which conditions may explain your symptoms and get clear guidance on the right next step, whether that is a primary care visit, lab work, or a conversation about weight loss treatment options.
Last reviewed for medical accuracy: 09/26/2026
Peptides are small chains of amino acids that act as signaling molecules in the body. In recent years, certain peptides have gained attention for their potential to support weight loss. Below, we’ll explore the main peptides used, how they work, what the research says, and important considerations before trying them.
These peptides have gone through rigorous testing and regulatory approval for weight-management or related metabolic benefits.
Glucagon-like peptide-1 (GLP-1) is a hormone produced in the gut that tells your brain you’re full and helps regulate blood sugar.
Semaglutide (Wegovy, Ozempic)
• Mechanism: Mimics GLP-1, slowing gastric emptying and curbing appetite.
• Evidence:
– Clinical trials (e.g., STEP trials) show 10–15% body-weight reduction over 68 weeks with lifestyle support.
– Improves blood sugar and cardiovascular markers.
• Common side effects: Nausea, diarrhea, constipation, occasional gallbladder issues.
Liraglutide (Saxenda, Victoza)
• Mechanism: Similar to semaglutide but shorter-acting.
• Evidence: Up to 8% weight loss over 56 weeks versus placebo when combined with diet/exercise.
• Common side effects: Nausea, vomiting, headache, potential risk of gallstones.
Exenatide (Byetta, Bydureon)
• Mechanism: Another GLP-1 mimic; less powerful weight loss than semaglutide but still beneficial.
• Evidence: 2–4% weight loss in type 2 diabetes trials; off-label use for weight management.
• Side effects: Similar gastrointestinal complaints.
Key point: These drugs require a prescription and regular follow-up. They work best alongside dietary changes and exercise.
These peptides stimulate your body to release more growth hormone, which can influence metabolism and body composition.
A few other peptides under research may help with weight control, but human data are limited.
Evidence grade varies widely.
• GLP-1 agonists (semaglutide, liraglutide) have the strongest, large-scale clinical evidence.
• GH-releasing peptides and others remain experimental with small or animal studies.
Lifestyle remains critical. Even the most effective peptides need to be paired with a balanced diet, regular exercise, and behavior changes.
Safety and monitoring. Prescription peptides are generally safe under medical supervision. Experimental peptides carry unknown long-term risks.
Consult your doctor.
• Discuss medical history, current medications, and treatment goals.
• Get baseline labs (blood sugar, lipids, liver/kidney function).
Understand side effects.
• Gastrointestinal upset is common with GLP-1 agonists.
• GH-related peptides can impact blood sugar and fluid balance.
Weigh cost and access.
• Most peptides require a prescription and can be expensive.
• Insurance coverage varies.
Beware of unregulated products.
• Only use peptides from reputable compounding pharmacies or manufacturers.
• Avoid buying from questionable online sources.
If you’re curious whether peptide therapy might be right for you—or if you’re experiencing unexplained weight changes—consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you identify potential health issues and decide whether to seek medical care.
Always remember: weight management is a multi-factorial process. No single therapy is a magic bullet. For any life-threatening or serious health concern, please speak to a doctor right away. If you’re thinking about peptide therapy or have alarming symptoms, a qualified healthcare provider can guide you through the safest, most effective options.
(References)
* Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056/NEJMoa1105816. PMID: 22029981.
* Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9. doi: 10.1016/j.cmet.2022.07.013. Epub 2022 Aug 18. PMID: 35985340.
* Gettman L. New Drug: Tirzepatide (Mounjaro(™)). Sr Care Pharm. 2023 Feb 1;38(2):50-62. doi: 10.4140/TCP.n.2023.50. PMID: 36751934.
* Véniant MM, Lu SC, Atangan L, Komorowski R, Stanislaus S, Cheng Y, Wu B, Falsey JR, Hager T, Thomas VA, Ambhaikar M, Sharpsten L, Zhu Y, Kurra V, Jeswani R, Oberoi RK, Parnes JR, Honarpour N, Neutel J, Strande JL. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024 Feb;6(2):290-303. doi: 10.1038/s42255-023-00966-w. Epub 2024 Feb 5. PMID: 38316982; PMCID: PMC10896721.
* Stefanakis K, Kokkorakis M, Mantzoros CS. The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism. 2024 Dec;161:156057. doi: 10.1016/j.metabol.2024.156057. Epub 2024 Oct 30. PMID: 39481534.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Ravussin E, Sanchez-Delgado G, Martin CK, Beyl RA, Greenway FL, O'Farrell LS, Roell WC, Qian HR, Li J, Nishiyama H, Haupt A, Pratt EJ, Urva S, Milicevic Z, Coskun T. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025 May 6;37(5):1060-1074.e4. doi: 10.1016/j.cmet.2025.03.011. Epub 2025 Apr 8. PMID: 40203836.
* Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025 May 30;15(6). doi: 10.3390/biom15060796. Epub 2025 May 30. PMID: 40563436; PMCID: PMC12190491.
* Zarkasi Z, Mudaliar RN, Majeed WA, Syed AA. Obesity and Metabolic Syndrome: Current Insights and Future Directions. Br J Hosp Med (Lond). 2025 Sep 25;86(9):1-20. doi: 10.12968/hmed.2025.0127. Epub 2025 Sep 5. PMID: 40994370.
* Ciudin A, Sapin H, Fan L, Dimitriadis GK, Zimner-Rapuch S, Curteis T, Clark LJ, Rubinstein M, Johansson E. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials. Adv Ther. 2026 May;43(5):2090-2105. doi: 10.1007/s12325-026-03523-5. Epub 2026 Mar 12. PMID: 41820778; PMCID: PMC13156185.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.